This trial studies an investigational medication injected into head and neck cancer tumors and affected lymph nodes for people age 60 or older who are planning to receive standard radiation therapy. All participants receive radiation, and half are randomly assigned to receive the investigational medication. Some may also receive a targeted medication by IV if prescribed by the trial doctor.
Watch this short video to learn about the NANORAY-312 clinical trial for head and neck cancer. It explains the purpose of the study and what participation involves, and it may serve as a helpful resource to begin the conversation with your doctor.
The goal of this clinical trial is to test how well the investigational medication works to stop or slow your cancer when used with radiation therapy, compared with radiation therapy alone.
Head and neck cancers can affect the lip, mouth, upper part of the throat (pharynx), and the area where the vocal cords are located (larynx).
During the clinical trial, all participants will receive standard radiation therapy. Your treatments will be coordinated by a physician team that includes your surgeon, radiation oncologist, and medical oncologist. There is a 1 in 2 (50%) chance, like the flip of a coin, that you will receive the investigational medication. This random assignment helps researchers compare the 2 groups fairly and avoid bias.
The investigational medication is a liquid injected directly into the tumor. This injection most often occurs in an operating or procedure room where your trial doctor (for example, the surgeon) will likely perform it under local or general anesthesia. The trial doctor may also inject the investigational medication into any lymph nodes in the neck that are affected by the cancer. These lymph nodes may or may not be injected on the same day as the tumor.
Regardless of whether you receive the investigational medication, some participants may also receive an additional targeted medication for head and neck cancer, called cetuximab, that is given through an IV (or a small tube temporarily placed in your vein). The trial doctor will help you determine if you should or should not receive this additional targeted medication.
Please see additional informational resources about the NANORAY-312 Clinical Trial HERE
See if you may qualify
Answer the following questions to see if you or someone you know may be eligible to take part in this study.
Please keep in mind:
Even if you believe you meet the eligibility criteria, joining a clinical trial is not guaranteed. Whether you’re referred or able to take part depends on a review by a qualified healthcare professional.
Note about privacy:
Email responses may not be encrypted. This means there’s a chance the messages could be seen by someone other than the intended recipient. We will avoid including sensitive personal information in emails whenever possible. However, we cannot guarantee that no sensitive information will be revealed indirectly.
About your information:
With your consent, we will use your answers to help determine whether you may be eligible for this clinical trial. You can withdraw your consent at any time.
Your information may be transferred to countries outside your country of residence, including the United States, which may have different data protection rules.
If you submit any personal information about someone else, you confirm that you have permission to do so.
Please read our Privacy policy for more details.